Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as C$0.47 and last traded at C$0.48, with a volume of 287813 shares. The stock had previously closed at C$0.54.
Medicenna Therapeutics Trading Down 1.1%
The firm’s 50 day moving average price is C$0.63 and its 200-day moving average price is C$0.93. The stock has a market cap of C$36.70 million, a P/E ratio of -2.93 and a beta of 2.90. The company has a debt-to-equity ratio of 3.30, a current ratio of 2.68 and a quick ratio of 4.65.
Medicenna Therapeutics (TSE:MDNA – Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported C($0.06) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative return on equity of 103.51% and a negative net margin of 533,640.00%. As a group, equities research analysts forecast that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current year.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.
Featured Stories
- Five stocks we like better than Medicenna Therapeutics
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.gif){kind=logo}
